News
PCSA
1.860
+1.09%
0.020
Weekly Report: what happened at PCSA last week (1102-1106)?
Weekly Report · 11/09 09:44
Processa Pharmaceuticals, Inc. Outlines Strategic Direction and Expected Capitalization of 309.3 million As-Converted Shares
NASDAQ · 11/06 02:41
Processa Pharmaceuticals, Inc. Appoints Gregory J. Flesher as Chief Operating Officer and Announces Key Leadership Additions
NASDAQ · 11/04 20:28
Processa Pharmaceuticals names Gregory Flesher COO, adds three executives
TipRanks · 11/04 14:18
Processa Pharmaceuticals Appoints Gregory J. Flesher Operations Chief
Benzinga · 11/04 13:06
*Processa Pharmaceuticals Names Gregory Flesher COO >PCSA
Dow Jones · 11/04 13:02
Weekly Report: what happened at PCSA last week (1026-1030)?
Weekly Report · 11/02 09:43
Processa Pharmaceuticals, Inc. Appoints Dr. Sheila Gujrathi as Executive Chair and Announces FDA Clearance of Phase 2 IND for VT-7208
NASDAQ · 10/29 22:42
Processa Advances Immunology Pipeline With New Leadership, Financing
TipRanks · 10/29 13:19
Processa Pharmaceuticals Appoints Sheila Gujrathi As Executive Chair, Effective Immediately, Succeeding Justin Yorke Resigns,
Benzinga · 10/29 12:49
Processa Pharmaceuticals Announces FDA Clears Its Investigational New Drug Application For Phase 2 Trial Of VT-7208 In Chronic Spontaneous Urticaria
Benzinga · 10/29 12:11
*Processa Pharma: Sheila Gujrathi Appointed Executive Chair of Bd >PCSA
Dow Jones · 10/29 12:10
*Processa Pharma: Cash Runway Expected to Fund Ops Into 2H of 2029 >PCSA
Dow Jones · 10/29 12:10
*Processa Pharma Enters Research Collaboration of Novel, Oral Macrocyclic Peptide-Based Neonatal Fc Receptor Antagonist Program From Generian Pharma >PCSA
Dow Jones · 10/29 12:09
*Processa Pharma: FDA Clears IND for Phase 2 Study of VT-7208 in Chronic Spontaneous Urticaria >PCSA
Dow Jones · 10/29 12:08
*Processa Pharma: Phase 2 Studies Planned in Food Allergy, Relapsing Multiple Sclerosis >PCSA
Dow Jones · 10/29 12:08
*Processa Pharmaceuticals Announces Corporate And Pipeline Progress Following Acquisition Of Vidya Therapeutics >PCSA
Dow Jones · 10/29 12:00
Weekly Report: what happened at PCSA last week (1019-1023)?
Weekly Report · 10/26 09:43
Weekly Report: what happened at PCSA last week (1012-1016)?
Weekly Report · 10/19 09:43
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/12 17:05
More
Webull provides a variety of real-time PCSA stock news. You can receive the latest news about Processa Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.